Onyx pharmaceuticals, the company committed to change the ways for the treatment of cancer. The company announced a team to discuss Carfilzomib clinical studies and market of multiple Myeloma online to improve the life style of cancer patients. Onyx announced to discuss the issues regarding the rapeutics and the treatment for cancer. The team will be available online around 11:00 A.M., today and the web address to reach them and discuss problems is http://www.onyx-pharma.com/view.cfm.32/event -calendar.
The announcement of Onyx pharmaceutical about the discussion on website is the result of the company’s plan to take over another Pharmaceutical company named Proteolix Inc, a private biopharmaceutical organization which is involved in the working and focus on the discovery and development of novel therapies for targeting proteasome in the treatment of hematological malignancies and strong tumors.
The leading compound by the Proteolix is carfilzomob that is used in number of clinical trial studies as an inhibitor for the next generation proteasome. It is also the part of clinical trials for the patients with refractory and relapse multiple myeloma.
Onyx Pharmaceuticals is a biopharmaceutical organization which has focused itself to improve the lives of the patients suffering from cancer. Onyx Pharmaceuticals is working on these specific lines with the collaboration of Bayer Health Care Pharmaceuticals.
Onyx Pharmaceuticals and Bayer Pharmaceutical has developed and marketed a small molecular drug named Nexavar. The Nexavar product is specially approved for the treatment of cancer related to liver and kidney. Nexavar is also observed and investigated in multiple clinical trials for different kinds of tumors.
Onyx Pharmaceuticals
Comments